CD8A and neoplasm: Even tumor cells can also express αvβ6 integrin to activate TGF-β and enhance CD103+CD69+CD8+ Trm cells, and these Trm cells may interfere with anti-PD-1/anti-PD-L1-mediated immunotherapeutic effects (173).